UBS Maintains Neutral on Chemours, Lowers Price Target to $16
UBS analyst Joshua Spector maintains Chemours (NYSE:CC) with a Neutral and lowers the price target from $18 to $16.
Stocks · News reference
Chemours Q2 2026 Earnings Call: Complete Transcript
Chemours (NYSE:CC) held its second-quarter earnings conference call on Wednesday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For real-time access to our entire
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Mizuho Maintains Outperform on Chemours, Lowers Price Target to $18
Why Is Chemours Stock Trading Higher Today?
Chemours PFAS settlement lifts shares as the $455 million deal clarifies liabilities, payment timing and future escrow obligations.